Ascletis Pharma

1672 · HKEX · China

Public Market Listing

1672HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Ascletis Pharma are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
0Approved
3Phase 3 / Filed
1Phase 1–2 / Early
8Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 3
GLP-1 receptorSmall molecule
ObesityType 2 Diabetes
Phase 3
Fatty acid synthase (FASN) · FASNSmall molecule
MASH / NASHGlioblastoma
Recurrent Glioblastoma
Phase 3
PD-L1Monoclonal antibody
HIVNon-Small Cell Lung CancerChronic Hepatitis BEndometrial Cancer
Phase 1
Thyroid hormone receptor-betaSmall molecule
Obesity

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
EnvafolimabPhase 1/2Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
Est. primary completion 2026-12 · NCT05024214 · CT.gov ↗
What to watch
EnvafolimabPhase 2Advanced Endometrial Cancer
Est. primary completion 2026-12 · NCT05112991 · CT.gov ↗
What to watch
2027 (3)
August 2027 (2)
DenifanstatPhase 3Acne Vulgaris
Est. primary completion 2027-08 · NCT07863193 · CT.gov ↗
What to watch
EnvafolimabPhase 2Solid Tumor
Est. primary completion 2027-08-30 · NCT04891198 · CT.gov ↗
What to watch
December 2027 (1)
EnvafolimabPhase 3Non-small Cell Lung Cancer
Est. primary completion 2027-12-30 · NCT06123754 · CT.gov ↗
What to watch
2028 (2)
July 2028 (2)
ASC30Phase 3Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
Est. primary completion 2028-07 · NCT07743450 · CT.gov ↗
What to watch
ASC30Phase 3Obesity, Overweight, Chronic Weight Management
Est. primary completion 2028-07 · NCT07743463 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
EnvafolimabPhase 2Biliary Tract Neoplasms
Est. primary completion 2029-06 · NCT04910386 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 December 2025Filing acceptedDenifanstatNMPA accepts denifanstat acne NDA
CN, NMPA · Ascletis Pharma · Source ↗
4 June 2025Topline resultDenifanstatChina phase III acne topline
Ascletis Pharma · Source ↗

Financial reports

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.3M$57M$206M$50Mreport ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.2M$42M$118M$42Mreport ↗